Clinical Trials
102 trialsVorinostat and Temozolomide in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NYMC195
New York Medical College
Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma
National Cancer Institute (NCI)
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
The Methodist Hospital Research Institute
Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
M.D. Anderson Cancer Center
Venetoclax to Augment Epigenetic Modification and Chemotherapy
Medical College of Wisconsin
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
Epigenetic Reprogramming in Relapse/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
City of Hope Medical Center
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation
Johns Hopkins All Children's Hospital
Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases
Thomas Jefferson University
MIBG With Dinutuximab +/- Vorinostat
New Approaches to Neuroblastoma Therapy Consortium
Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
M.D. Anderson Cancer Center
Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma
Indiana University
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
PRAVO
Oslo University Hospital
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
The University of Texas Health Science Center at San Antonio
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
Roswell Park Cancer Institute
Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer
Virginia Commonwealth University
MK-0683-029
Merck Sharp & Dohme LLC
MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
M.D. Anderson Cancer Center
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
National Cancer Institute (NCI)
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma
Emory University
MK-0683-098
Merck Sharp & Dohme LLC
Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors
Johns Hopkins All Children's Hospital
Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
M.D. Anderson Cancer Center
Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma
Fox Chase Cancer Center
SAHA
Columbia University
Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
Yale University
MK-0683-074
Merck Sharp & Dohme LLC
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
AIDS Malignancy Consortium
Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Ohio State University Comprehensive Cancer Center
NSCLC
Fox Chase Cancer Center
A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)
Merck Sharp & Dohme LLC
Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer
City of Hope Medical Center
Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer
Virginia Commonwealth University
Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma
Ohio State University Comprehensive Cancer Center
Epigenetic Reprogramming in Relapse AML
Medical College of Wisconsin
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
National Institutes of Health Clinical Center (CC)
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
National Cancer Institute (NCI)
VICTORY-J
Kanazawa University
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Celgene
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
Stanford University
Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast
University of California, San Francisco
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)